Sangart, Inc., a San Diego, CA-based global biopharmaceutical company, has received $50m in Series G equity funding from existing investor Leucadia National Corporation.
Led by President and CEO Brian O’Callaghan, Sangart develops and commercializes targeted rescue therapies for patients in acute ischemic crisis.
The company intends to use the funds to advance the development of the MP4OX product in severe traumatic hemorrhagic shock and the MP4CO product in sickle cell disease.
FinSMEs
24/05/2012